Living with Wilson A patient-led project

← Back to all answers

Where Can My Family Get Wilson Disease Carrier Screening?

Genetic carrier testing for ATP7B mutations is available through medical genetics clinics, specialist hepatology centres, and some commercial labs — here is how to find it quickly in most countries.

Finding carrier testing for Wilson disease is more straightforward than it sounds once you know where to look. Your relatives do not need to wait months for a neurology or liver specialist — in most countries a referral to a medical genetics clinic, or a direct order through a gastroenterologist or hepatologist, is enough to get a blood sample collected and sent for ATP7B sequencing within a few weeks.1 This page explains your options country by country, what to ask for, and how to speed things along.

Why carrier testing matters — and what it can and cannot tell you

Wilson disease is caused by two faulty copies of the ATP7B gene, one from each parent.2 If you have the disease, each of your biological parents carries at least one mutation (they are almost always healthy carriers themselves). Your siblings have a one-in-four chance of being affected and a two-in-four chance of being carriers. Your partner, unless they happen to come from a family with Wilson disease, is almost certainly not at elevated risk — but testing is still worthwhile before the two of you consider having children.3

Carrier testing looks for pathogenic ATP7B variants in a blood sample. A positive result (one mutation found) means the person is a carrier — healthy, and no treatment needed, but important to know when family planning is on the table. Two mutations found means the person likely has Wilson disease themselves and should have a full clinical workup. No mutations found is reassuring but not 100% certain, because the test panels cover the most common variants and may miss rare private mutations.4

See family screening for a fuller explanation of who should be tested and why.

How to get tested quickly: a country-by-country overview

Country / Region Best first step Typical wait Notes
United States Ask your Wilson disease specialist to write a referral or order directly 2–6 weeks Commercial labs (GeneDx, Invitae, Ambry) accept direct physician orders; some accept self-pay
Canada Referral to provincial medical genetics clinic or metabolic disease centre 4–12 weeks Covered under provincial health; expedited if index case already confirmed
United Kingdom GP referral to regional genetics service 6–18 weeks routine; faster if urgent NHS Genomic Medicine Service has Wilson disease on its rare disease panel
Germany / Austria / Switzerland Hepatologist or neurologist order; university hospital genetics departments 4–8 weeks Covered by statutory insurance (Krankenkasse) with specialist referral
China Specialist centre (Beijing Tiantan, Anhui Zhongke Zhongyi) → genetic testing lab Weeks to months Access uneven outside tier-1 cities; some private labs offer ATP7B panels
Australia GP or specialist referral to state genetics service 4–10 weeks Medicare covers testing when a first-degree relative has confirmed WD
Elsewhere Contact the Wilson Disease Association (wilsonsdisease.org) for centre referrals Varies International patient organisations maintain lists of testing centres

Practical steps to reduce waiting time

Step 1 — Get a letter from your specialist. A written statement from your treating physician that you have confirmed Wilson disease will dramatically shorten the pre-authorisation process for your relatives. Ask your doctor to include your ATP7B mutation results (if known) so the lab can target the most likely variants first.

Step 2 — Call genetics before waiting for a paper referral. Many genetics clinics accept phone or online self-referrals, especially if you can cite a confirmed first-degree relative. The formal GP or specialist letter can follow.

Step 3 — Ask about direct-to-consumer or private-pay options. In the US, labs like Invitae offer ATP7B panels at fixed prices without insurance. In Canada and the UK, private labs exist but costs are significant (USD 250–800 range is common [unverified]). This is sometimes worth paying if the public wait is very long and family planning decisions are time-sensitive.

Step 4 — Bring your own mutation data. If your sequencing report identified your specific variants, share the report. Labs can run a targeted variant test, which is cheaper, faster, and easier to interpret than a full gene panel.

Step 5 — Contact a patient organisation. The Wilson Disease Association (US-based, international reach) and the European Association for the Study of the Liver patient network can recommend the nearest experienced centre and sometimes facilitate faster appointments.5

What happens at the appointment

The actual test is a routine blood draw. Your relative will have a brief consultation — often by video — to discuss what the result means before the sample is taken. Results typically come back in two to four weeks from a genetics lab, faster if a targeted variant test is ordered. A genetic counsellor (or the referring specialist) will explain the result and, if needed, recommend follow-up.6

If the relative is found to carry two ATP7B mutations, clinical evaluation follows: liver function tests, copper studies (serum ceruloplasmin, 24-hour urine copper), and a slit-lamp eye exam looking for Kayser-Fleischer rings.7 This does not mean they are sick — many people with two mutations are still pre-symptomatic — but it does mean starting treatment early, before copper causes damage.

A note on your partner

Unless your partner has a personal or family history of Wilson disease, their baseline risk of carrying an ATP7B mutation is roughly 1 in 90 in most populations.8 That sounds low, but because Wilson disease requires two mutations, the risk of having an affected child is 1 in 4 only if both partners are carriers. For most couples, partner testing is most important when you are planning a pregnancy and want complete reassurance. Genetic counselling before testing — even a 30-minute telehealth call — is worth arranging so results are interpreted in the right context.

This page is for information only and does not replace medical advice. Please talk with a geneticist or your Wilson disease specialist before making decisions based on carrier test results.

References


  1. Schilsky, Michael L., Eve A. Roberts, Jeff M. Bronstein, et al. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2025): E41–E90. https://doi.org/10.1002/hep.32801. 

  2. Czlonkowska, Anna, et al. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. 

  3. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. 

  4. Ferenci, Peter. “Regional Distribution of Mutations of the ATP7B Gene in Patients with Wilson Disease: Impact on Genetic Testing.” Human Genetics 120, no. 2 (2006): 151–159. https://doi.org/10.1007/s00439-006-0202-5. 

  5. Alkhouri, Naim, Regino P. Gonzalez-Peralta, and Valentina Medici. “Wilson Disease: A Summary of the Updated AASLD Practice Guidance.” Hepatology Communications 7, no. 5 (2023): e0150. https://doi.org/10.1097/HC9.0000000000000150. 

  6. Trocello, Jean-Marc, Souleiman El Balkhi, France Woimant, et al. “Relative Exchangeable Copper: A Promising Tool for Family Screening in Wilson Disease.” Movement Disorders 29, no. 4 (2014): 558–562. https://doi.org/10.1002/mds.25763. 

  7. Kim, Gu-Hwan, Jeong Yoon Yang, Jung-Young Park, et al. “Estimation of Wilson’s Disease Incidence and Carrier Frequency in the Korean Population by Screening ATP7B Major Mutations.” Genetic Testing 12, no. 3 (2008): 395–399. https://doi.org/10.1089/gte.2008.0016. 

  8. Park, H-D, C-S Ki, S-Y Lee, and J-W Kim. “Carrier Frequency of the R778L, A874V, and N1270S Mutations in the ATP7B Gene in a Korean Population.” Clinical Genetics 75, no. 4 (2009): 405–407. https://doi.org/10.1111/j.1399-0004.2008.01132.x. 

This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.